approximately 90% of clients in the Washington PRC program misused prescription opioids by doctor shopping, frequent cycling through emergency departments, and prescription forgery. WSHRSA attempted to limit such misuse by restricting PRC clients to one primary-care provider, one narcotics prescriber, one pharmacy, and one hospital for nonemergency care. In addition, WSHRSA could require prior authorization for all opioid prescriptions.
Morbidity and Mortality Weekly Report www.cdc.gov/mmwr
During 1999-2006, the number of poisoning deaths in the United States nearly doubled, from approximately 20,000 to 37,000, largely because of overdose deaths involving prescription opioid painkillers (1) . This increase coincided with a nearly fourfold increase in the use of prescription opioids nationally (2) . In Washington, in 2006, the rate of poisoning involving opioid painkillers was significantly higher than the national rate (1) . To better characterize the prescription opioids associated with these deaths and to reexamine previously published results indicating higher drug overdose rates in lower-income populations (3), health and human services agencies in Washington analyzed overdose deaths involving prescription opioids during [2004] [2005] [2006] [2007] . This report describes the results of that analysis, which found that 1,668 persons died from prescription opioid-related overdoses during the period (6.4 deaths per 100,000 per year); 58.9% of decedents were male, the highest percentage of deaths (34.4%) was among persons aged 45-54 years, and 45.4% of deaths were among persons enrolled in Medicaid. The age-adjusted rate of death was 30.8 per 100,000 in the Medicaid-enrolled population, compared with 4.0 per 100,000 in the non-Medicaid population, an age-adjusted relative risk of 5.7. Methadone, oxycodone, and hydrocodone were involved in 64.0%, 22.9%, and 13.9% of deaths, respectively. These findings highlight the prominence of methadone in prescription opioid-related overdose deaths and indicate that the Medicaid population is at high risk. Efforts to minimize this risk should focus on assessing the patterns of opioid prescribing to Medicaid enrollees and intervening with Medicaid enrollees who appear to be misusing these drugs.
For this analysis, the Washington State Department of Health defined an overdose death involving prescription opioids as a death in Washington during 2004-2007 of a state resident whose death certificate had 1) a manner of death of "accidental" or "natural"; 2) one or more contributing causes coded to "poisoning by narcotics" or a "mental and behavioral disorder due to use of opioids" (based on International Classification of Diseases, 10th Revision codes T40.0-T40. 6 and F11*); 3) specific words compatible with an acute drug intoxication recorded in any of the cause of death fields (e.g., "overdose"); and 4) a prescription opioid term in any of the cause of death fields. Examples of prescription opioid terms sought on manual review of the certificates were "oxycodone," "methadone," and "hydrocodone." Although morphine is a prescription opioid painkiller, it is also a metabolite of heroin. Therefore, mention of morphine on a death certificate was only accepted as evidence that a death was prescription opioidrelated when the certificate specified that the morphine was a prescription drug. As a result, 82 deaths involving morphine and no other opioids (36.6% of all deaths in which morphine was mentioned) were excluded from this analysis.
The Washington State Health and Recovery Services Administration (WSHRSA), which operates Medicaid and several associated medical-assistance programs, determined which deaths occurred among persons who were enrolled in Of these, 2,194 (96.1%) had a death certificate that included a term indicating acute drug intoxication. Of these 2,194, a total of 1,668 (76.0%) had a death certificate that included a prescription opioid term and were included in this analysis. The age-adjusted prescription opioid overdose rate was 6.4 per 100,000 per year ( Table 1 ). The male mortality rate was 1.4 times the female rate. Rates increased with age to a peak of 15.0 per 100,000 in the 45-54 years age group and then declined.
Among all decedents, 758 (45.4%) were enrolled in Medicaid at some point during the year of their death. Medicaid-enrolled decedents had an age distribution comparable with that of decedents statewide. However, the percentage of females was greater among Medicaid-enrolled decedents (52.2%) than among decedents statewide (41.1%). A total of 34 Medicaidenrolled decedents were in the PRC program, representing 4.5% of all Medicaid-enrolled decedents.
The risk for prescription opioid overdose death varied substantially by Medicaid status ( Table 2 ). The crude annual risk for prescription opioid overdose death was approximately one in 6,757 in the Medicaid-enrolled population and one in 172 in the Medicaid-enrolled PRC program population.
Medical examiners and coroners recorded methadone on death certificates nearly three times more often than the next most common opioid, oxycodone (Table 3) . At least one nonopioid prescription drug was reported in 54.6% of the deaths. A benzodiazepine was listed on the death certificate in 20.9% of the deaths, and an antidepressant in 31.7%. An illegal drug was reported in 21.8% of the deaths. Cocaine was involved in 15.7%, methamphetamine in 5.5%, heroin this analysis indicate that deaths from prescription opioid drug overdose in Washington occurred disproportionately among males and persons aged 45-54 years. This analysis also is the first to show an increased risk among persons enrolled in Medicaid. The age-adjusted risk of such a death for a Medicaid enrollee was 5.7 times the risk for a person not enrolled in Medicaid. These findings are similar to previous research showing a higher risk for such deaths in lower-income populations (3) and can be used to better focus preventive interventions. The cause of the higher death rate in Washington's Medicaid enrolled population might be related, in part, to differences in opioid prescribing in the Medicaid population. Although comparable prescribing data for Medicaid and non-Medicaid populations are not available for Washington, studies indicate that opioid prescribing rates among Medicaid enrollees are at least twofold higher than rates for persons with private insurance (6, 7) . In one of these studies, both the percentage of patients with pain being treated with opioids and the opioid dose per prescription were higher in Medicaid patients than in non-Medicaid patients (6) . The higher death rate among Medicaid enrollees in Washington also might be related to a higher prevalence of substance abuse and other mental health problems, which has been found in other Medicaid populations (8) . In this analysis, medical examiners and coroners reported the presence of an illegal drug (e.g., cocaine, methamphetamine, and heroin) in nearly a fifth of deaths, and psychotherapeutic drugs such as benzodiazepines and antidepressants were reported in a high proportion of deaths.
Methadone, a drug used both for treatment of heroin addiction and as a long-acting, inexpensive painkiller, has become increasingly prominent among drugs involved in overdoses, both nationally and in state studies (1, 9, 10 The findings in this report are subject to at least two limitations. First, the number of overdoses involving prescription opioids might be underestimated because 1) such drugs might not have been specified on the death certificates even though they contributed to death and 2) some deaths involving morphine and no other opioids were not included because the morphine detected might have been a metabolite of heroin. Second, some deaths labeled unintentional might have been suicides by poison or vice-versa, but the net effect of such errors likely is minimal.
Surveillance for prescription drug overdose deaths should be improved. Drugs listed on death certificates for overdoses are coded into broad categories, making identification of specific drugs difficult. Use of uncoded text in the cause-of-death fields on death certificates, as was done in this study, might be a promising strategy at the state or national level. Health authorities (e.g., state and local health departments, coroner and medical examiner offices, and substance abuse programs) in other states should examine trends in and risks for prescription opioid-related overdose death in their jurisdictions, especially among Medicaid clients. 
Perceived Insufficient Rest or Sleep Among AdultsUnited States, 2008
The importance of chronic sleep insufficiency is underrecognized as a public health problem, despite being associated with numerous physical and mental health problems, injury, loss of productivity, and mortality (1, 2) . Approximately 29% of U.S. adults report sleeping <7 hours per night (3) and 50-70 million have chronic sleep and wakefulness disorders (1) . A CDC analysis of 2006 data from the Behavioral Risk Factor Surveillance System (BRFSS) in four states showed that an estimated 10.1% of adults reported receiving insufficient rest or sleep on all days during the preceding 30 days (4) . To examine the prevalence of insufficient rest or sleep in all states, CDC analyzed BRFSS data for all 50 states, the District of Columbia (DC), and three U.S. territories (Guam, Puerto Rico, and U.S. Virgin Islands) in 2008. This report summarizes the results, which showed that among 403,981 respondents, 30.7% reported no days of insufficient rest or sleep and 11.1% reported insufficient rest or sleep every day during the preceding 30 days. Females (12.4%) were more likely than males (9.9%) and non-Hispanic blacks (13.3%) were more likely than other racial/ethnic groups to report insufficient rest or sleep. State estimates of 30 days of insufficient rest or sleep ranged from 7.4% in North Dakota to 19.3% in West Virginia. Health-care providers should consider adding an assessment of chronic rest or sleep insufficiency to routine office visits so they can make needed interventions or referrals to sleep specialists. BRFSS* is a state-based, random-digit-dialed telephone survey of the noninstitutionalized U.S. civilian population aged ≥18 years, which is conducted by state health departments in collaboration with CDC (5 (4) examining data from four states. Statistical significance was determined by using t-tests. Unless otherwise indicated, all comparisons mentioned in this report were significant at the p<0.001 level.
Among the 403,981 adult respondents, an estimated 30.7% reported no days of insufficient rest or sleep in the preceding 30 days, 41.3% reported 1-13 days, 16.8% reported 14-29 days, and 11.1% reported 30 days ( Table 1 ). The prevalence of adults reporting no days of insufficient rest or sleep in the preceding 30 days increased with age; persons aged ≥45 years were more likely to report no days than adults aged <45 years. Hispanic (38.8%) and other non-Hispanic racial/ethnic groups (35.4%) were more likely to report no days in comparison with non-Hispanic whites (27.9%) and non-Hispanic blacks (30.4%). Men (33.6%) were more likely to report no days than women (28.1%). Retired persons (43.8%) were most likely to report no days of insufficient rest or sleep in comparison with adults reporting other types of employment status (p=0.003). Those with less than a high school diploma or general education development certificate (GED) (37.9%) also were more likely to report no days of insufficient rest or sleep in comparison with those with a high school diploma or GED (33.8%) or with some college or college degree (28.0%). Finally, reports of no days of insufficient rest or sleep were similar among adults of varying marital status, although never married adults (31.6%) were more likely to report no days than members of an unmarried couple (28.4%; p=0.005).
The percentage of adults reporting insufficient rest or sleep every day during the preceding 30 days generally declined with age ( Table 1 ). The percentage was highest among persons aged 25-34 years (13.8%) and lowest among persons aged ≥65 years (7.4%). Non-Hispanic blacks (13.3%) were significantly more likely than non-Hispanic whites (11.2%) to report 30 days of insufficient rest or sleep. Females were more likely to report 30 days of insufficient rest or sleep than males (12.4% versus 9.9%, respectively). Persons who reported being unable to work (25.8%) and unemployed respondents (13.9%) were significantly more likely to report 30 days of insufficient rest or sleep than respondents who were employed (9.9%), retired (9.5%; p=0.011), or a student or homemaker (11.1%). In comparison with persons with some college education or a college degree (9.6%), insufficient rest or sleep was significantly more likely to be reported by persons with less than a high school education (14.3%) and among those with a high school diploma or GED (13.2%). Compared with married respondents (11.1%), those who were divorced, widowed, or separated were more likely to report insufficient sleep (16.0%). Percentages for never married persons (10.6%) and members of an unmarried couple (12.1%) were similar to those for married adults (11.1%; p=0.139).
The distribution of reported days of insufficient rest or sleep varied among states and territories ( Table 2 ). The lowest age-standardized prevalences of 30 days of insufficient rest or sleep in the preceding 30 days were observed in North Dakota (7, 8) .
The high prevalence of insufficient rest or sleep was concentrated in the southeastern United States. The causes of the geographic variations found cannot be determined by this study. However, geographic variations in occupational factors (e.g., shift work opportunities and extended work schedules) and lifestyle choices (e.g., use of technology), and the distribution of related common chronic diseases (e.g., obesity [9] , depression, hypertension, heart disease, and stroke), many of which also are concentrated in the Southeast, might play a role and should be examined further (10) .
The major causes of sleep loss are overlapping and include lifestyle and occupational factors that reflect broad societal factors (e.g., work hours and access to technology), and specific sleep disorders (1) . Further studies are needed to explain the sex and racial/ethnic differences apparent in these results. Women are underrepresented in studies of sleep and sleep disorders (7) . Further research also is needed to examine the relationship between sleep during pregnancy and postpartum and sleeprelated diseases, such as depression, which are more prevalent in women (7) . Racial and ethnic minorities disproportionately report sleep durations that are associated with increased mortality and might contribute to health disparities, and they are overrepresented in low socioeconomic environments that might compromise sleep quality (7) . In this analysis, persons unable to work expressed the greatest prevalence of perceived rest or sleep insufficiency, which might be the result of mental distress or medical problems, disabilities, or other conditions that prevent them from being employed. What is added by this report?
Insufficient rest or sleep prevalence estimates from adults in the 50 United States, the District of Columbia, and three U.S. territories (Guam, Puerto Rico, and U.S. Virgin Islands) from the 2008 BRFSS substantiate previous findings, add support for sex and race/ethnicity differences, and characterize geographic variations in the state-based reports of rest or sleep insufficiency.
What are the implications for public health practice?
Health-care providers should consider adding an assessment of chronic rest or sleep insufficiency to routine office visits so they can make needed interventions or referrals to sleep specialists.
The findings in this report are subject to at least three limitations. First, the definitions of "enough (sufficient)" sleep and "rest" and responses to the survey question were subjective and were not accompanied by reports of hours of sleep per night; therefore, this analysis cannot be compared directly with studies of sleep duration. Because the survey question also did not distinguish between "rest" and "sleep," respondents might vary in their interpretation of the questions and the terms. Finally, institutionalized persons and persons residing in households without landline telephones are not included in the survey. Therefore, the findings of this report are not generalizable to those populations.
According to the National Sleep Foundation, adults need 7-9 hours of sleep each night. Health-care professionals should evaluate patients who report chronic insufficient rest or sleep and advise them of effective behavioral strategies including keeping a regular sleep schedule; avoiding stimulating activities within 2 hours of bedtime; avoiding caffeine, nicotine, and alcohol in the evening; sleeping in a dark, quiet, well-ventilated space; and avoiding going to bed hungry. ¶ Pharmacologic intervention also might be warranted. Although few formal clinical practice guidelines are available for assessing and treating sleep insufficiency and sleeping disorders, a multidisciplinary team, including a sleep specialist, might be required for proper treatment (1).
Cronobacter Species Isolation in Two Infants -New Mexico, 2008
Cronobacter spp. (formerly Enterobacter sakazakii) are rare causes of infant septicemia and meningitis, resulting in death in approximately 40% of cases (1) . Since 1958, 120 cases of Cronobacter infection in infants have been reported, an average of fewer than three cases per year worldwide. Powdered infant formula (PIF), which is not sterile, has been implicated repeatedly as a vehicle of Cronobacter infection; consequently, the World Health Organization (WHO) has issued guidelines for safer preparation, handling, and storage of PIF (2, 3) . This report describes isolation of Cronobacter spp. in two nonhospitalized, unrelated infants (one male and one female) in New Mexico in 2008; one infant developed severe brain injury and hydrocephalus, and the other infant died. An investigation by the New Mexico Department of Health (NMDOH) determined that PIF consumption was the only known risk factor in the two cases, although the sources of the Cronobacter spp. could not be determined. Cronobacter spp. were not isolated from sealed canisters of formula associated with the two infants, and clinical isolates from the infants differed by pulsed-field gel electrophoresis (PFGE). However, a Cronobacter organism was isolated from an opened canister of formula consumed by the male infant and was indistinguishable from an isolate from his postmortem blood culture. Education of formula preparers regarding potential PIF contamination, universal adoption of WHO PIF preparation guidelines, and continued improvement of PIF manufacturing processes might help prevent Cronobacter infection among infants (3).
On November 18, 2008, NMDOH received notification from a hospital laboratory that Cronobacter spp. (formerly Enterobacter sakazakii*) had been isolated from the cerebrospinal fluid of a female infant aged 7 weeks. The isolate was ¶ Additional guidance on good sleep practices from the National Sleep Foundation is available at http://www.sleepfoundation.org/article/ask-the-expert/sleephygiene.
* In 2008, the taxonomy of Enterobacter sakazakii was updated, resulting in creation of five novel species belonging to a new genus, Cronobacter, which is contaxic with E. sakazakii (4 Case Reports Case 1. The female infant was born in September 2008 at full term by vaginal delivery without complications. Her mother had received prenatal care. The infant had been fed PIF exclusively since birth. The infant was well until approximately age 3.5 weeks, when a family member noted that she had an axillary temperature of 100.9°F (38.3°C) and took her to a hospital emergency department. Records for this visit noted a normal rectal temperature, normal fontanel, and overall healthy appearance. The infant was discharged without further testing or treatment. However, during the following week, the infant became notably fussier and began vomiting. Her illness progressed during early November, when at age 6.5 weeks she exhibited seizure-like activity. She was admitted to a hospital on November 14. On physical examination the infant was found to have a bulging anterior fontanelle, horizontal nystagmus, a positive Brudzinski sign with neck rigidity, and dehydration. Cerebrospinal fluid cultures collected during this admission yielded a Cronobacter organism; blood cultures were negative for Cronobacter. The infant was placed on intravenous antibiotic therapy, including ampicillin and cefotaxime. She was transferred to a second hospital within 24 hours of this admission for further evaluation and diagnostic testing.
At the second hospital, a computed tomography scan of the head revealed thick-walled hypodense lesions that were identified as abscesses. Within 24 hours of admission to the second hospital the infant was transferred to a third hospital where pediatric specialists in infectious disease and neurosurgery were available. On November 16, at the third hospital, a ToRCH workup (testing for toxoplasmosis, other infections, rubella, cytomegalovirus, and herpes simplex virus) was conducted and was negative. Serial magnetic resonance imaging conducted during November 17, 2008-February 4, 2009, revealed multiple brain abscesses, diffuse brain injury, and hydrocephalus with lateral third and fourth ventricle dilation. Fluid obtained through percutaneous aspiration of an abscess in the right frontal region of the brain yielded a Cronobacter organism that was resistant to cefazolin but susceptible to ceftriaxone, ciprofloxacin, gentamicin, and trimethoprim-sulfa. Treatments administered during hospitalization at the third hospital included intravenous meropenem, vancomycin, gentamicin, acyclovir, baclofen, and phenobarbital and multiple percutaneous aspirates of the left and right ventricles of the brain; placement of a vetriculoperitoneal shunt was not required. An electroencephalogram performed on January 12, 2009, was interpreted as abnormal because of a diffusely slow background. In addition, frequent multifocal epileptiform discharges for multiple areas of cortical hyperexcitability were noted that could have led to localization-related seizures. After 11.5 weeks in the hospital, the infant was discharged on February 6, 2009, with severe brain injury, hypertonicity resulting from central nervous system damage, and hydrocephalus.
Case 2. The male infant was born in April 2008 at 40 weeks' gestation by vaginal delivery without complications. His mother had received prenatal care. The infant was breastfed exclusively until age 6 months and then began transitioning to PIF and age-appropriate foods. Other than a history of mild-moderate eczema that was being treated with oral antihistamines, moderate-dose topical steroids, and topical antibiotics, the infant was healthy, as confirmed by medical records and a visit by a trained new-parent support worker on November 10, 2008. The following day, at age 7 months, he died unexpectedly while taking his usual nap at home. A Cronobacter organism was found in the blood culture obtained during autopsy. However, aside from mild eczema, no congenital or histopathologic abnormalities were noted during postmortem examination. Therefore, the Cronobacter isolate was attributed to postmortem bacterial overgrowth, and the autopsy report listed sudden infant death syndrome (SIDS) as the cause of death.
Epidemiologic and Environmental Investigations
Initial review of the two cases by CDC and FDA investigators determined that the female infant had been infected with Cronobacter spp. and the male infant had been colonized with Cronobacter spp. without clear evidence of infection. Ingestion of PIF was the only identified risk factor for Cronobacter exposure for the two infants. The two infants had consumed the same brand of PIF but had no other common exposures. PIF preparers reported washing their hands before preparing formula and washing bottle components by hand between feedings for the female infant and in the dishwasher for the male infant. Additionally, they reported following the manufacturer's instructions for preparing and handling PIF. In the female infant's household, water used for PIF reconstitution had been boiled, cooled, and then stored in the kitchen in a plastic container. Reconstituted PIF was not reheated, and new bottles were prepared for every feeding (approximately every 3 hours). In the male infant's household, PIF had been reconstituted by using refrigerated bottled water or tap water. The water was not boiled or heated before use.
Investigations were conducted at both infants' homes, which included collecting environmental samples and samples of PIF and other infant food. However, neither the container used to store water for formula preparation nor canisters of formula fed to the female infant before illness onset were available for testing; therefore, the lot numbers of PIF fed to the female infant before illness could not be determined. The PIF collected from the female infant's home had been fed to her after her symptoms began. In addition, NMDOH and FDA collected 30 unopened canisters of the same brand of PIF from retail stores where the parents of the two infants reported obtaining formula. These canisters had the same lot numbers and expiration dates as the formula collected from the infants' homes. Samples from the store canisters were submitted to the NMDOH Scientific Laboratory Division and FDA for testing; no Cronobacter spp. were isolated.
Environmental surface swabs and food and nonfood samples were cultured using standard methods. Opened and unopened canisters of PIF were tested by following the enrichment and isolation methodology for Cronobacter organisms outlined by FDA. † Suspected environmental and clinical isolates were confirmed as Cronobacter spp. through the use of conventional biochemical testing and DNA sequencing. Pulsed-field gel electrophoresis (PFGE) was performed on all Cronobacter isolates by using the standard PFGE methodology CDC employs for Escherichia coli O157:H7.
Although the two infants had consumed the same brand of formula, their clinical Cronobacter isolates had different PFGE patterns (Table) . None of the samples obtained from the home of the female infant yielded Cronobacter spp. However, PIF from an opened canister and the vacuum cleaner filter from the home of the male infant yielded Cronobacter spp. The clinical Cronobacter isolate from the male infant and the Cronobacter isolate from the PIF canister sample from his home had indistinguishable PFGE patterns; however, the vacuum cleaner Cronobacter isolate from the same home had a different PFGE pattern (Table) . Cronobacter spp. were not isolated from any of the unopened canisters of PIF in either home. † Available at http://www.fda.gov/food/scienceresearch/laboratorymethods/ ucm114665.htm. In response to the isolation of Cronobacter organisms from these infants, NMDOH issued recommendations regarding infant feeding practices, including breastfeeding when possible and using proper formula preparation procedures. NMDOH also requested notification from the three largest commercial laboratories in New Mexico of any results indicating Cronobacter spp. isolation from infants aged <1 year. In addition, a Health Alert Network message was sent to all laboratories across the state alerting them to these increased surveillance activities. No additional cases were identified. Editorial Note: This report describes the isolation of Cronobacter spp. from two nonhospitalized, unrelated infants in 2008 in New Mexico. Isolation of this organism from human specimens is rare and makes these cases notable. The female infant had documented Cronobacter infection that led to severe brain injury and hydrocephalus. Although a Cronobacter organism was isolated from the male infant at autopsy, the role of that organism in the infant's apparent death from SIDS is unknown. Isolation of Cronobacter spp. in association with SIDS has not been reported previously.
Previous investigations have found Cronobacter spp. cultured from prepared formula, unopened PIF containers, and the environment where PIF was reconstituted, clearly implicating PIF as the source of outbreaks. Other than an improperly prepared intravenous nutrition solution implicated in one outbreak (5) , no other clear source of Cronobacter infection has been identified. Cronobacter spp. rarely are isolated from human intestines (6), and mother-to-child transmission has not been documented. The isolation of a Cronobacter organism from the vacuum cleaner filter in the male infant's household indicated the organism's presence in the home environment. However, the vacuum isolate differed by PFGE pattern from the clinical isolate, demonstrating that at least two distinct strains of Cronobacter spp. were present concurrently in the household. Although Cronobacter spp. have been isolated from household vacuum cleaners previously (7), the source of the Cronobacter organisms in such situations and the implications for human health are unknown. Isolation of Cronobacter organisms with indistinguishable PFGE patterns from the male infant's clinical specimen and an opened PIF canister in his home suggest contaminated PIF as a source of Cronobacter spp. for this infant. Because Cronobacter spp. were not isolated from unopened canisters of the PIF associated with the two cases in New Mexico, the PIF associated with the male infant might have been contaminated extrinsically. Canisters of PIF consumed by the female infant before her illness began were not available for testing, and the source of her infection could not be determined.
Although isolation is rare, the extent of Cronobacter infection has not been well enumerated in the United States; formal surveillance and reporting systems exist only in Minnesota, where a single infant case has been identified since 2005. A national FoodNet § survey in 2002 estimated the annual incidence of invasive Cronobacter infection at one per 100,000 infants aged <1 year and at 8.7 per 100,000 low birthweight infants (<2,500 g [5.5 lbs]). ¶ Despite limited surveillance for this infection in the United States and elsewhere, at least 12 outbreaks of severe Cronobacter infection have been observed worldwide since 1958, generally among infants hospitalized in intensive-care units (2) . Although sporadic cases of community-acquired Cronobacter infection have been reported, outbreaks of community-acquired disease have not. However, enhanced surveillance might produce a more accurate estimate of the Cronobacter disease burden and insight into risk factors; accordingly, FoodNet is expected to soon begin piloting surveillance for Cronobacter infections in the United States.
Infants throughout the world consume PIF, some exclusively. PIF preparers should be aware that PIF is not sterile and can contain pathogenic organisms (e.g., Cronobacter spp.). Preparers also should be aware that PIF can be contaminated extrinsically (although mechanisms for such contamination are not well defined) and that bacteria can multiply rapidly in reconstituted PIF. Consequently, WHO has developed guidelines for preparation of PIF, including reconstitution with water
What is already known on this topic?
Cronobacter spp. are a rare cause of infant septicemia and meningitis with 40% mortality and often are associated with powdered infant formula (PIF).
What is added by this report?
This report describes two unrelated cases of isolation of Cronobacter spp. from infants in New Mexico, at least one likely caused by contamination of PIF.
Promotion by public health agencies of universal adoption of World Health Organization PIF preparation guidelines and continued improvement of PIF manufacturing processes might help reduce Cronobacter illness among infants. § The Foodborne Diseases Active Surveillance Network (FoodNet) of CDC's Emerging Infections Program collects data from 10 U.S. states on diseases caused by enteric pathogens transmitted commonly through food. ¶ Available at http://www.who.int/foodsafety/publications/micro/es.pdf. hot enough to inactivate Cronobacter organisms (3). Universal adoption of these guidelines can aid in implementation of safer PIF preparation, storage, and handling. In the United States and elsewhere, recommendations are to breastfeed infants when possible, use sterile liquid infant formula in high-risk settings (e.g., neonatal intensive-care units and hospital nurseries), and adhere to the safest available PIF preparation procedures (8, 9) . Manufacturing sterile powdered infant formula, perhaps by using irradiation in combination with other techniques, could prevent infant disease (10) . Additionally, further precautions to prevent extrinsic contamination of PIF are needed. Engineering of PIF packaging to prevent introduction of contaminated hands, scoops, or other items might help prevent additional infant disease. 
Announcement

National Epilepsy Awareness MonthNovember 2009
November is National Epilepsy Awareness Month. Epilepsy, which affects nearly 2.5 million persons in the United States, is characterized by recurrent, unprovoked seizures (1) . Delayed recognition of these seizures and subsequent inadequate treatment increases the risk for additional seizures, disability, decreased health-related quality of life, and, in rare instances, death (2) (3) (4) .
In their day-to-day work, most law enforcement and emergency response personnel are able to recognize citizens who are experiencing seizures and provide the appropriate intervention steps for responding to a person during a seizure. On any given shift, however, some law enforcement officers unknowingly might encounter persons having seizures who appear to be confused, are unable to communicate, or exhibit behaviors inappropriate to time and place. Such persons having a seizure might not obey an officer's directives and unknowingly might become combative, resulting in inappropriate arrest, possible injury, and in some cases, death.
This year, the Epilepsy Foundation, in partnership with CDC, is conducting a national education and outreach program to educate and train law enforcement officers, police cadets, and emergency response personnel across the country to increase their recognition of seizures and promote safe and appropriate intervention practices for persons with epilepsy. The centerpiece of this effort is the First Responders Training Program, consisting of two modules. The first, the recently released Law Enforcement Training Curriculum, includes a brief presentation and a DVD outlining the vital steps in seizure recognition and first aid for law enforcement personnel. Approximately 30,000 officers have participated in the law enforcement training program to date. The second, a module designed specifically for emergency response personnel, will instruct first responders in seizure recognition and response.
Additional information about the First Responders Training Program is available online (http://www.epilepsyfoundation. org/about/professionals/emergency/index.cfm). Additional information about epilepsy and the national campaign is available from the Epilepsy Foundation by telephone (800-332-1000) or online (http://www.epilepsyfoundation.org). Information in Spanish is available by telephone (866-748-8008) or online (http://www.fundacionparalaepilepsia.org).
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Announcement
Drowsy Driving Prevention WeekNovember 2-8, 2009
November 2-8 is Drowsy Driving Prevention Week. Driving while drowsy is a major contributor to an estimated 100,000 motor vehicle crashes per year and results in more than 1,500 deaths nationwide (1) . Sleepiness demonstrably impairs safe driving by reducing alertness and slowing reaction time.
Several factors can contribute to drowsy driving (1). Although insufficient sleep duration and fragmented sleep are significant causes of drowsiness, circadian rhythms cause increased sleepiness during the afternoon, even with adequate sleep. Sedating medications and consumption of alcohol also cause drowsiness, which is amplified with sleep deprivation. Untreated sleep disorders also can contribute to excessive sleepiness.
Groups at higher risk for sleep-related crashes include bus, truck, and other commercial drivers; shift workers and persons with more than one job or irregular work hours; persons with untreated sleep disorders such as sleep apnea and narcolepsy; and drivers aged <26 years, especially males (2). In addition, adolescents are more likely than older drivers to be sleepdeprived because of school schedules, social activities, and shifting circadian rhythms (3).
Good sleep practices (http://www.cdc.gov/sleep/hygiene. htm) include establishing a regular sleep schedule, avoiding intense physical activity or large meals before bedtime, and ensuring an environment conducive to sleep. For short-term improvement of alertness, drivers can park and take a 15-20 minute nap or consume caffeine. High-intensity lighting, nap breaks during shifts, and breaks from repetitive work can reduce the risk for drowsy driving among shift workers. Diagnosis and treatment of sleep disorders also are important in reducing the risk for drowsy driving. Additional information is available from the National Sleep Foundation (http://drowsydriving. org) and CDC (http://www.cdc.gov/sleep).
Announcement
World Pneumonia DayNovember 2, 2009
Pneumonia kills more children than any other illness; of the approximately 10 million children aged <5 years who die each year worldwide, 2 million die from pneumonia (1) . Streptococcus pneumoniae (pneumococcus) and Haemophilus influenzae type b (Hib) account for approximately half of pneumonia deaths globally in children aged 1 month-5 years (2,3). Much of this disease burden is vaccine-preventable. In the United States, seven-valent pneumococcal conjugate and Hib vaccines are recommended for infants and children aged <2 years as part of the routine infant immunization schedule and have reduced morbidity and mortality from pneumococcal and Hib disease (4, 5) . Collaborative international efforts are expanding use of these vaccines in developing countries (6, 7) .
Viruses such as respiratory syncytial virus, parainfluenza virus, measles, and influenza also are a major cause of pneumonia. Access to vaccines, antivirals and supportive healthcare measures reduces the burden of infections from these viruses.
To raise awareness of the effects of pneumonia globally, the first World Pneumonia Day, November 2, 2009, is being promoted by a coalition of 40 major health, humanitarian relief, advocacy, faith-based, government, and other organizations; CDC and UNICEF are providing technical assistance. Events are scheduled at CDC and elsewhere in the United States, and in other countries. Additional information is available at http:// worldpneumoniaday.org. † Calculated by summing the incidence counts for the current week, the 2 weeks preceding the current week, and the 2 weeks following the current week, for a total of 5 preceding years. The total sum of incident cases is then divided by 25 weeks. Additional information is available at http://www.cdc.gov/epo/dphsi/phs/files/5yearweeklyaverage.pdf. § Not reportable in all states. Data from states where the condition is not reportable are excluded from this table, except starting in 2007 for the domestic arboviral diseases and influenza-associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phs/infdis.htm. ¶ Includes both neuroinvasive and nonneuroinvasive. Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, VectorBorne, and Enteric Diseases (ArboNET Surveillance). Data for West Nile virus are available in Table II . ** The names of the reporting categories changed in 2008 as a result of revisions to the case definitions. Cases reported prior to 2008 were reported in the categories: Ehrlichiosis, human monocytic (analogous to E. chaffeensis); Ehrlichiosis, human granulocytic (analogous to Anaplasma phagocytophilum), and Ehrlichiosis, unspecified, or other agent (which included cases unable to be clearly placed in other categories, as well as possible cases of E. ewingii). † † Data for H. influenzae (all ages, all serotypes) are available in Table II . § § Updated monthly from reports to the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Implementation of HIV reporting influences the number of cases reported. Updates of pediatric HIV data have been temporarily suspended until upgrading of the national HIV/AIDS surveillance data management system is completed. Data for HIV/AIDS, when available, are displayed in Table IV 6  2  9  119  118  -83  134  3,543  3,785  -0  2  13  12  Louisiana  -2  8  96  117  79  132  420  5,159  7,651  -0  1  12  9  Oklahoma  2  3  18  135  123  62  66  612  3,832  3,955  1  1  20  63  70  Texas  §  N  0  0  N  N  -556  696  22,041 26,015  -0  1  2  9  Mountain  18  26  60  1,227  1,326  86  171  265  6,784  9,470  -5  11  200  238  Arizona  1  3  9  162  113  29  54  88  2,168  2,788  -1  7  69  91  Colorado  8  8  26  394  462  29  52  122  1,933  3,005  -1  6  60  45  Idaho  §  5  3  10  148  163  1  2  13  76  135  -0  1  3  12  Montana  §  2  2  11  114  79  -1  5  60  103  -0  1  1  3  Nevada  §  -2  11  91  97  -30  93  1,414  1,803  -0  2  16  15  New Mexico  §  -2  8  91  95  27  24  52  913  1,110  -1  3  21  36  Utah  -5  12  176  282  -3  11  157  417  -1  2  27  33  Wyoming  §  2  1  4  51  35  -1  5  63  109  -0  1  3  3  Pacific  47  50  130  2,118  2,430  180  543  764  22,851 25,389  -2  8  98  124  Alaska  -2  7  94  85  -15  24  550  436  -0  3  15  18  California  16  34  56  1,376  1,597  143  463  657  19,270 20,847  -0  3  22  40  Hawaii  -0  2  14  39  -11  24  496  506  -0  3  23  16  Oregon  §  12  7  18  322  386  37  20  42  775  987  -1  3  35  48  Washington  19  7  74  312  323  -43  71  1,760  2,613  -0  2  3  2  American Samoa  -0 Table I . § Contains data reported through the National Electronic Disease Surveillance System (NEDSS). -0  1  2  2  -0  0  ---0  2  4  2  Pacific  -3  13  147  103  3  3  10  121  123  3  3  14  150  242  Alaska  -0  1  2  6  -0  1  2  5  -0  2  6  6  California  -2  10  120  59  2  2  8  89  89  2  2  8  100  177  Hawaii  N  0  0  N  N  -0  1  1  3  -0  1  4  5  Oregon  §  -0  3  15  29  -0  2  11  4  1  0  6  27  30  Washington  -0  12  10  9  1  0  3  18  22  -0  6  13  24  American Samoa  N -0  13  64  82  5  1  161  122  232  Arkansas  †  3  5  38  225  85  -0  10  33  44  5  0  61  58  44  Louisiana  -2  8  90  71  -0  0  ---0  1  2  6  Oklahoma  -0  45  42  32  -0  13  30  36  -0  98  49  142  Texas  †  12  52  304  2,058  1,081  -0  1  1  2  -0  6  13  40  Mountain  -18  32  733  703  -2  6  80  95  -0  3  21  39  Arizona  -3  10  170  198  N  0  0  N  N  -0  2  5  12  Colorado  -5  12  207  127  -0  0  ---0  1  1  1  Idaho  †  -1  5  65  26  -0  0  -11  -0  1 -3  17  215  152  -0  3  15  12  -0  0  -3  Washington  1  6  58  234  315  -0  0  ---0 1  8  17  333  356  -1  11  67  59  -1  3  31  83  Washington  44  11  85  642  556  11  2  17  160  125  7  2  11  125  85  American Samoa  -0  1  -2  -0  0  ---1  2  3  1  C.N.M.I.  ---------------Guam  -0  0  -13  -0  0  ---1  1  -14  Puerto Rico  -9  40  344  601  -0  0  ---0  2  8 4  9  79  373  410  8  5  46  240  224  Arkansas  §  -0  2  15  10  -0  4  22  12  Louisiana  -0  3  11  17  -0  3  13  11  Oklahoma  2  3  20  120  91  2  1  7  52  57  Texas  §  2  5  59  227  292  6  3  34  153  144  Mountain  5  10  22  373  476  1  4  16  184  214  Arizona  1  3  7  127  168  1  2  10  96  95  Colorado  3  3  7  117  120  -1  4 N  1  3  8  144  113  Florida  16  15  36  629  573  2  2  13  103  112  3  19  32  799  841  Georgia  5  8  25  322  354  2  1  5  55  62  -14  227  616  538  Maryland  §  -0  1 Table IV , which appears quarterly. † Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance). Data for California serogroup, eastern equine, Powassan, St. Louis, and western equine diseases are available in Table I . § Not reportable in all states. Data from states where the condition is not reportable are excluded from this table, except starting in 2007 for the domestic arboviral diseases and influenza-associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phs/infdis.htm. ¶ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
